TY - JOUR
T1 - CD-NP
T2 - A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart
AU - Martin, Fernando L.
AU - Sangaralingham, S. Jeson
AU - Huntley, Brenda K.
AU - McKie, Paul M.
AU - Ichiki, Tomoko
AU - Chen, Horng H.
AU - Korinek, Josef
AU - Harders, Gerald E.
AU - Burnett, John C.
PY - 2012/12/18
Y1 - 2012/12/18
N2 - Natriuretic peptides (NPs) are cardioprotective through the activation of guanylyl cyclase (GC) receptors A and B. CD-NP, also known as cenderitide, is a novel engineered NP that was designed to uniquely serve as a first-in-class dual GC receptor agonist. Recognizing the aldosterone suppressing actions of GC-A activation and the potent inhibitory actions on collagen synthesis and fibroblast proliferation through GC-B activation, the current study was designed to establish the anti-fibrotic actions of CD-NP, administered subcutaneously, in an experimental rat model of early cardiac fibrosis induced by unilateral nephrectomy (UNX). Our results demonstrate that a two week subcutaneous infusion of CD-NP significantly suppresses left ventricular fibrosis and circulating aldosterone, while preserving both systolic and diastolic function, in UNX rats compared to vehicle treated UNX rats. Additionally we also confirmed, in vitro, that CD-NP significantly generates the second messenger, cGMP, through both the GC-A and GC-B receptors. Taken together, this novel dual GC receptor activator may represent an innovative anti-fibrotic therapeutic agent.
AB - Natriuretic peptides (NPs) are cardioprotective through the activation of guanylyl cyclase (GC) receptors A and B. CD-NP, also known as cenderitide, is a novel engineered NP that was designed to uniquely serve as a first-in-class dual GC receptor agonist. Recognizing the aldosterone suppressing actions of GC-A activation and the potent inhibitory actions on collagen synthesis and fibroblast proliferation through GC-B activation, the current study was designed to establish the anti-fibrotic actions of CD-NP, administered subcutaneously, in an experimental rat model of early cardiac fibrosis induced by unilateral nephrectomy (UNX). Our results demonstrate that a two week subcutaneous infusion of CD-NP significantly suppresses left ventricular fibrosis and circulating aldosterone, while preserving both systolic and diastolic function, in UNX rats compared to vehicle treated UNX rats. Additionally we also confirmed, in vitro, that CD-NP significantly generates the second messenger, cGMP, through both the GC-A and GC-B receptors. Taken together, this novel dual GC receptor activator may represent an innovative anti-fibrotic therapeutic agent.
UR - http://www.scopus.com/inward/record.url?scp=84871315815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871315815&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0052422
DO - 10.1371/journal.pone.0052422
M3 - Article
C2 - 23272242
AN - SCOPUS:84871315815
SN - 1932-6203
VL - 7
JO - PLoS One
JF - PLoS One
IS - 12
M1 - e52422
ER -